p73 has been identi®ed as a protein which shares signi®cant homology with the tumor suppressor p53. We found two new types of splicing variant mRNAs for p73 expressed in MCF-7 cells which we named p73g and e. Sequence analysis revealed that these mRNAs encode variant p73 proteins bearing distinct carboxy-terminal structures, which are also dierent from the previously reported variants p73a and b. The mRNAs encoding p73g and e as well as a and b were con®rmed to be expressed in normal human tissues in varied patterns. All of these splicing variants activated promoter with the p53-binding consensus sequence, but to dierent degrees. Furthermore, suppressive eects of p73a, g and e, but not b, on endogenous p53 activity were observed when transiently expressed in HepG2 and MCF-7 cells. These results suggested that the carboxy-terminal regions of p73 which were altered by alternative splicing aect these transactivation abilities and modulate the functions of p73 molecules.
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Keywords: p73; splicing variant; p53; transcriptional activity p53 has been described as the master guardian of the genome. This molecule regulates the responses of cells to genotoxic stimuli and protects vulnerable cells from malignant transformation (reviewed in Ko and Prives, 1996; Levine, 1997) . Recently, a gene encoding a protein with signi®cant homology to p53 was discovered and the gene product was named p73 (Kaghad et al., 1997) . p73 has functional as well as structural similarities to p53 (Jost et al., 1997; Kaghad et al., 1997) . It has been reported that p73 transiently expressed in the cells activated transcription of a reporter plasmid containing p53 responsive elements in the promoter region. Likewise, p73 induced p21 gene expression, resulting in inhibition of growth of a neuroblastoma cell line and SAOS-2 cells.
When full-length p73 cDNA was synthesized by reverse transcriptase-polymerase chain reaction (RT ± PCR) using puri®ed polyA-RNA of MCF-7 cells as a template, we obtained four types of cDNA clone for p73. Sequence analysis revealed that we cloned two new splicing variants of p73 in addition to p73a and b which have been already reported (Kaghad et al., 1997) . We named these new clones p73g and p73e (see the last paragraph of the text). By comparison with the nucleotide sequence of p73a cDNA, p73g and e cDNAs appeared to lack exon 11 and both exons 11 and 13 of the p73 gene, respectively (Figure 1a) . The translation product of the p73g transcript was presumed to be composed of 475 amino acids (aa) including the unique C-terminal 76 aa. On the other hand, p73e protein was estimated to contain 555 aa residues which included 46 aa corresponding to the amino acid sequence of p73g (portion from aa 400 ± 445) and 110 aa equivalent to the C-terminal sequence of p73a (Figure 1b and c). As p73b cDNA was reported to lack exon 13 and p73b protein has a unique 5 aa sequence at the C-terminal instead of the C-terminal 142 aa of p73a (Kaghad et al., 1997) , at least four kinds of p73 protein diering at their C-terminal portions were presumed to be produced in MCF-7 cells.
To examine the expression patterns of these four variant mRNAs in MCF-7 and COS cells, which were used for p73 cDNA cloning by Kaghad et al. (1997) , polyA-RNAs from these cell lines were analysed by PCR using primers 1 and 2, shown in Figure 1a , after RT reaction for semi-quantitative estimation of each RNA species (Siebert and Larrick, 1992) . After 30 rounds of PCR, the products with the expected sizes were detected by ethidium bromide staining in 3% agarose gels (data not shown). These PCR products were veri®ed by Southern blotting analysis (Figure 2a) . In MCF-7 cells, four bands with the expected sizes, i.e. 437 bp, 342 bp, 289 bp and 194 bp derived from p73a, b, g and e, respectively, were observed. The bands representing p73a, b and g became detectable after 20 cycles of PCR, although all four bands were seen after 25 cycles. On the other hand, p73g and e were not detected in COS cells even after 25 cycles of PCR, although faint bands for g and e were seen after 30 cycles. These results suggested that the expression patterns of the four p73 splicing variants are dierent between MCF-7 and COS cells.
To examine the tissue-speci®c expression of these four variant mRNAs, total RNA samples extracted from normal human tissues including the brain, heart, lung, liver, fetal liver, spleen, pancreas, kidney, small intestine, skeletal muscle, testis and thymus (obtained from Clontech) were analysed by RT ± PCR followed by Southern blotting as described above. Transcripts of all splicing variants were detected in all tissues after 35 cycles of PCR (data not shown). In many tissues, p73a and b mRNAs were produced at levels higher than those of g and e. Among the tissues examined, we found that p73 mRNA was highly expressed in the brain, lung, testis and thymus. Semiquantitative Figure 1 (a) Schematic representation of p73 splicing variant cDNA structures. Full length p73 cDNA was synthesized by RT ± PCR from 1 mg of PolyA-RNA of MCF-7 cells. Reverse-transcription reaction was done by Superscript II (GIBCO ± BRL) using the RT1 primer (see below). One tenth part of the obtained cDNA was then used for the ®rst PCR done by Pfu DNA polymerase using primers 1S and RT1, as recommended by the manufacturer (Stratagene). Condition of PCR using an GeneAmp PCR System 9700 (Perkin Elmer) was as follows: 30 cycles of denaturation at 958C for 1 minute (min), annealing at 558C for 1 min and primer extension at 728C for 5 min, with an initial denaturation step at 958C for 5 min and a ®nal extension step at 728C for 10 min. One 25th part of the ®rst PCR product was used for the second PCR as a template under the same protocol using primers 2S and 2R. The primers used in this experiment were as follows; RT: 5'-TGACTCAGGCTGTCCACAGG-3', 1S: 5'-AGAGC-GAGCTGCCCTCGGAG-3', 2S: 5'-GGAAGATGGCCCAGTCCACC-3' and 2R: 5'-TGGACACACAGGAAGGAGAG-3'. Final PCR products were subcloned into BamHI ± XhoI and BglII ± XhoI sites of pcDNA3 (Invitrogen) and pCMV-Tag1 (Stratagene), respectively. Sequence analysis revealed that four types of cDNA clone for p73 were obtained. While p73b cDNA was reported to lack exon 13 of the p73 gene, p73g and e cDNA lacked exon 11 and both exon 11 and exon 13, respectively. Arrows indicate locations and directions of primers used for RT ± PCR analysis, and the bar under exon 12 indicates the location of the probe used in Southern blotting analysis in Figure 2 . (b) Predicted amino acid sequences of the C-terminal regions of p73 splicing variants. The positions of introns within p73 gene are denoted above the p73a sequence. (c) Translation products of p73 splicing variants, p73 deletion mutants and p53. TAD, DBD and OD in p73a indicate the putative regions of transactivation, DNA binding and oligomerization domains of p73, respectively. The closed box in the p73b C-terminus and hatched box in that of p73g indicate respective unique sequences. p73e includes the sequences corresponding to p73g and a C-terminal regions shown between arrows and between arrow heads, respectively. p73DC424 and p73DC269 encode the amino-terminal 423 aa and 268 aa of p73a, respectively. Levels of activation of p53BCS promoter are summarized from the data shown in Figure 3 . p53 cDNA was obtained by RT ± PCR New p73 variants Y Ueda et al analysis of p73 splicing variant mRNA expression was then performed in these four tissues as described above (Figure 2b ). In all of these tissues, the expression of p73a mRNA was dominant. In the testis, p73g mRNA was expressed at much higher levels than p73b mRNA, although p73b mRNA was expressed at higher levels than p73g and e mRNAs in the other three tissues. These results indicated that mRNAs of p73g and e as well as a and b are actually expressed in normal human tissues, and their expression patterns vary among these tissues. This suggested that each p73 splicing variant has a dierent function. The isoforms of some transcription factors generated by alternative splicing have been reported to have dierent biochemical functions from each other (reviewed in Lopez, 1995) . Therefore, to examine whether the function of p73 is also regulated by alternative splicing, we investigated the transactivation ability of each p73 splicing variant on promoter with the p53-binding consensus sequence (p53BCS promoter) in cultured cells, using the reporter plasmid pCAST2Bluc, in which the p53-binding consensus sequence comprising two copies of 5'-GAG-CATGCCCGGGCATGCTC-3' is placed upstream of the luciferase gene (Kiyono et al., 1994) . The expression plasmids of four p73 splicing variants, the C-terminal deletion mutants of p73, p73DC424 and DC269, and p53 were designed to be expressed in cells from total RNA sample of normal human testis (Clontech) by using primers RT2 for reverse transcription and 3S and 3R for PCR. p73DC424 and p73DC269 cDNA were prepared by PCR from pcDNA3-p73a as a template by using primers 4S and 4R for DC424, and 4S and 5R for DC269. The primers used in this experiment were as follows; RT2: 5'-AACCCAAAATGGCAGGGGAG-3', 3S: 5'-TTGGCAGCCAGACTGCCTTC-3', 3R: 5'-TCAGTGGGGAACAAGAAGTG-3', 4S: 5'-GGAAGATGGCCCAGTCCACC-3', 4R: 5'-TCACTTGTTCATGCCCCCGTGCAC-3' and 5R: 5'-TCACCGGTTCATGCCCCCTACAC-3'. PCR conditions were same in legend of Figure 1a . PCR products were subcloned into BamHI ± EcoRI and BglII ± XhoI sites of pcDNA3 (Invitrogen) and pCMV-Tag1 (Stratagene), respectively Figure 2 mRNA species of p73 splicing variants in cell lines and normal human tissues. (a) RT ± PCR-Southern blotting analysis of p73 transcripts in MCF-7 and COS cells. Aliquots of 1 mg of PolyA-RNA from MCF-7 and COS cells were reverse-transcribed into cDNA with the primer (5'-TGACTCAGGCTGTCCACAGG-3') using Superscript II (GIBCO ± BRL). One tenth part of cDNA reaction mixture was then used for PCR done by Taq polymerase (Takara), as recommended by the manufacturer. Ampli®cations were performed in an GeneAmp PCR System 9700 (Perkin Elmer) as follows: 10, 15, 20, 25 or 30 cycles of denaturation at 958C for 30 seconds (s), annealing at 658C for 30 s and primer extension at 728C for 60 s, with an initial denaturation step at 958C for 5 min and a ®nal extension step at 728C for 5 min. The reactions were carried out using primer 1 (5'-CAGCAGCAGCTCCTACAGAG-3') and 2 (5'-TACTGCTCGGGGATCTTCAG-3') shown in Figure 1a . PCR products were electrophoresed in 3.0% agarose gels and transferred onto Hybond N + membranes (Amersham). The ®lters were hybridized with the probe corresponding to a region of exon 12 of the p73 gene labeled with a-32 P-dCTP by random primers (Pharmacia). The probe was obtained by PCR using 5'-CGGGATGCTCAACAACCATG-3' and 5'-TGACGAGGCTGGGGTCGGCGTG-3' as primers and pcDNA3-p73a as a template, as described above. As a positive control, PCR products ampli®ed from plasmid pcDNA3-p73a, b, g and e were used. Four bands with sizes of 437 bp, 342 bp, 289 bp and 194 bp were derived from p73a, b, g and e respectively. (b) Aliquots of 2 mg of total RNA extracted from human brain, lung, testis and thymus (Clontech) were analysed by RT ± PCR ± Southern blotting as described above New p73 variants Y Ueda et al under the control of the cytomegalovirus promoter in the pcDNA3 vector (Invitrogen). SAOS-2 and Jurkat cells, which do not produce endogenous p53 protein (Cheng and Haas, 1990; Diller et al., 1990; Hassapoglidou et al., 1993) , were transfected with one of the above expression plasmids for p73 derivatives and p53 together with pCAST2Bluc. The cells transfected with p-55Bluc, which lacks the p53-binding sequence from pCAST2Bluc (Kiyono et al., 1994) , instead of pCAST2Bluc, was used as a negative control. The Figure 3 (a) Activation of p53BCS promoter by p73 splicing variants. SAOS-2 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) (Nissui) containing 10% fetal calf serum (FCS), 584 mg/ml glutamine, 50 units/ml penicillin and 50 mg/ml streptomycin at 1.5610 5 cells per well 35 mm in diameter. At 12 hours (h) after seeding, the cells were transfected with plasmids using FuGENE6 transfection reagent (Boehringer Mannheim). Each transfection mixture contained 0.3 mg of pCAST2Bluc or p55Bluc, 1 mg of expression plasmid encoding p73 splicing variants (pcDNA3-p73a, b, g and e), p73 deletion mutants (pcDNA3-p73DC424 and p73DC269), p53 (pcDNA-p53) or pcDNA3 vector only (shown as v) and 3 ml of FuGENE6. Jurkat cell cultures were began at a density of 2610 6 cells per 60 mm dish in RPMI-1640 medium (Nissui) containing 10% FCS, 300 mg/ml glutamine, 50 units/ml penicillin and 50 mg/ml streptomycin, and transfected with 1.5 mg of reporter plasmid and 3.0 mg of expression plasmid using 20 ml of SuperFect transfection reagent (QIAGEN). Cells were harvested at 24 h after transfection and luciferase activity in cell extracts was measured. Luciferase activity of pCAST2Bluc was normalized with that of p-55Bluc. Fold activation was quanti®ed relative to the level of luciferase activity from cells transfected with the reporter plasmid and pcDNA3 vector. All the transfection experiments were performed at least three times, and the mean results are shown here. (b) Detection of exogenous p73 splicing variants and deletion mutants. SAOS-2 cells were transiently transfected using FuGENA6 transfection reagent with 2 mg of expression plasmids encoding each variant with a FLAG-tag at the N-terminal end, as described above. Anti-FLAG tag Western blotting of whole-cell extracts collected at 24 h after transfection was performed as described previously (Hijikata et al., 1993) . (c) Levels of luciferase reporter plasmid pCAST2Bluc expression in SAOS-2 cells transfected with increasing amounts of pcDNA3-p73a, b, g or e. Experimental procedures were the same as in panel a luciferase activities in pCAST2Bluc-transfected cells were normalized by the activities in p-55Bluc-transfected cells. As expected from the results of a previous study (Jost et al., 1997) , all p73 variants and p73DC424 as well as p53 induced luciferase activity from the co-transfected pCAST2Bluc, while p73DC269 in which a quarter of the DNA binding domain had been deleted had no signi®cant eect on the transactivation (Figure 3a) . However, the magnitudes of transactivation activities varied among these proteins. p53, p73b, and p73DC424 showed markedly higher transactivation activities. The luciferase activities induced by these proteins were estimated to be at least 1000-fold higher than that in controls transfected with vector plasmid. p73b appeared to have stronger transactivation potential than p73DC424, which was similar to that of p53. On the other hand, the activities of p73a, g and e were signi®cantly lower than that of p53. The luciferase activities induced by p73a, g and e in SAOS-2 cells were about 0.5%, 6% and 0.1% of that activated by p53, respectively. Similar results were obtained in Jurkat cells. We con®rmed above all results of reporter assay by normalization using dual luciferase reporter system (Promega) in which internal control plasmid (pRL-TK) with sea pansy luciferase gene was used. To investigate the production levels of these variants and deletion mutants in transfected cells, each product in the cell lysate was analysed by Western blotting analysis. To detect each molecule under the same conditions, expression plasmids in which the FLAG tag sequence was introduced at the N-terminal of each p73 variant and mutant were constructed and used in transfection experiments. We con®rmed that FLAG-tagged products also induced the transcription of the reporter gene similarly to the authentic proteins shown in Figure 3a (data not shown). In the lysates of SAOS-2 cells transfected with each construct, each protein with the expected size was detected by anti-FLAG tag antibody (Figure 3b ). We also found some dierences in the production levels of the four variants. However, there was no correlation between the magnitude of luciferase gene activation and the amount of each product. Furthermore, the dierences of luciferase induction levels among the variants were not aected by titration of the amount of expression plasmid used for transfection (Figure 3c ). These results indicated that the observed dierences of transcriptional activating properties of p73 variants were not due to dierences in the amounts of products. Thus, it is suggested that the C-terminal regions of p73a, g and e may contain some structures that suppress the transcriptional activation of p73. In particular, the region of 11 aa residues from exon 14 seemed to play an important role in the suppressive eect, because this portion was shared between p73a and e. In addition, structural variety at the C-terminal regions of p73 variants may contribute to the quantitative dierences in the products in the cells, as shown above.
To determine whether p73 in¯uences endogenous p53 activity, HepG2 and MCF-7 cells, which are known to produce wild-type p53 protein (Bartek et al., 1990; Puisieux et al., 1993; Tominaga et al., 1993) , were used for reporter gene assay (Figure 4) . Cotransfection of negative control vector with the reporter plasmid resulted in marked elevation of luciferase activity possibly by endogenous wild-type p53. However, luciferase activity was reduced when p73a, g or e expression plasmid, which were shown to have much lower activities on the p53BCS promoter than p53 itself, were used in the cotransfection experiment. This reduction was further enhanced by transfection with increasing amounts of these plasmids (data not shown). Figure 4 Suppressive eects of exogenous p73 on endogenous p53 activity. HepG2 cells were cultured in DMEM containing 10% FCS, 584 mg/ml glutamine, 50 units/ml penicillin and 50 mg/ ml streptomycin at 5610 5 cells per well 35 mm in diameter. MCF-7 cells were cultured in Minimum Essential Medium (GIBCO ± BRL) containing 10% FCS, 1 mM sodium pyruvate, 5 mg/ml penicillin and streptomycin at 3610 5 cells per well. Twelve hours after seeding, both types of cells were transiently transfected with 0.3 mg of reporter plasmid and 1 mg of pcDNA3-p73a, b, g, e, DC424 or DC269, pcDNA3-p53 or pcDNA3 vector using 3 ml of FuGENE6 transfection reagent. Cells were harvested 24 h after transfection, and luciferase activity in cell extracts was determined. The level of activity normalized with the control experiment using pcDNA3 vector was arbitrarily set as 100%. Values are averages of three experiments, each with at least three independent transfections It was reported previously that p73a does not directly interact with p53 (Kaghad et al., 1997) . Therefore, these results suggested that overproduced exogenous p73 binds to the p53 binding element of the reporter plasmid in competition with endogenous p53, although the possibility that p73 indirectly suppress p53 activity via p73-responsive gene expression cannot be excluded. This hypothesis is supported by the observation that p73DC269, which was expected to lack DNA binding ability and had little eect on the p53BCS promoter, did not reduce luciferase activity. This suppressive eect of p73 on p53 activity was also observed in SAOS-2 cells, which lack endogenous p53 production, transfected with 0.01 mg of pcDNA3-p53 and 1 mg of pcDNA3-p73a, g and e (data not shown). p73 may reduce the p53 activity and aect the proliferation of tumor cells by competing binding with p53-responsive promoters, when higher levels of active p73 than p53 are expressed.
We showed here that there are at least four kinds of p73 protein diering in the C-terminal regions by alternative splicing, and these variants show varied transactivation activities on p53BCS promoter. From our observations, the level of p73b mRNA expression, which activates p53BCS promoter similarly to p53, was fairly low in the testis which contains many actively proliferating cells. This tissue-speci®c expression pattern of p73b is reasonable if we suppose that p73b acts like p53 and induces p21 production followed by cell cycle arrest (El-Deiry et al., 1993 . The expression patterns of these variants in each cell type will provide insight into their authentic functions.
The functional roles of the C-terminal regions of p73 variants are still unclear. One possibility is that the Cterminal region aects the molecular interactions of p73 because it was previously shown using the yeast two-hybrid system that p73b forms a complex with itself and p53, while p73a does not (Kaghad et al., 1997) . Although we do not know whether p73g and e interact with themselves or p53, it is possible that varied activities of p73 variants on the p53BCS promoter are due to dierences in oligomerization. Further investigations to determine the functions of p73 splicing variants are currently in progress in our laboratory.
During the review process of this paper, De Laurenzi et al. reported two new splicing variants of p73 and called as g and d (De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, AnnicchiaricoPetruzzelli M, Levrero M and Melino G. (1998) . J. Exp. Med., 188, 1763 ± 1768.). The g was identical to g described in our paper, but the d was dierent. In order to avoid confusion, we changed the name of our d to e. In their paper, it was reported that p73g had a lower tendency to form homotypic interactions than b and no interaction with p53 in yeast two-hybrid assay. These results may support our results that p73g had lower transactivation activities than b in SAOS-2 in Jurkat cells, and had suppressive eect on endogenous p53 activity in HepG2 and MCF-7 cells.
